What You Should Know About the CMS Proposed 340B Payment Change

The Centers for Medicare & Medicaid Services (CMS) has proposed a Medicare outpatient payment change that could reshape how 340B hospitals evaluate high-cost, clinic-administered drugs.

Under the Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) proposed rule, reimbursement for many outpatient drugs purchased through the 340B program would decrease from Average Sales Price (ASP) plus 6% to ASP minus 33.4%.¹

If finalized, the proposal could reduce reimbursement for many 340B-acquired outpatient drugs, potentially shifting health systems to a more disciplined, drug-by-drug assessment of reimbursement, acquisition cost, payer mix, and site of care.

Why This Matters

CMS has described the proposal as an effort to align reimbursement more closely with hospital acquisition costs. It remains subject to the federal rulemaking process, and the final policy could differ in rate, scope, timing, or exemptions.

For health systems, the proposal is more than a reimbursement issue, potentially influencing how health systems evaluate the economics of specialty care delivery across a range of outpatient settings, particularly:

• Hospital outpatient departments
• Provider-based clinics
• Oncology infusion
• Ophthalmology
• Immunology
• Other high-cost Part B drug settings

The proposal could shift hospitals from broad 340B optimization toward more precise drug-, payer-, and site-specific margin management.

The Practical Impact of CY 2027 OPPS Proposed Rule for Health Systems

Together, OPPS reimbursement and 340B acquisition cost shape the economics of many outpatient-administered drugs. A material reduction in Medicare payment could compress margins in settings where high-cost Part B products are administered to Medicare beneficiaries, particularly when the 340B discount does not offset the proposed reimbursement reduction.

The central question is no longer only whether a drug is 340B eligible; it is whether that drug, for that payer, in that site of care, remains financially sustainable.

Exposure will vary by organization. Medicare mix, drug utilization, provider-based clinic footprint, billing practices, acquisition cost, and site-of-care strategy will determine whether the proposal creates limited pressure or a more significant need to redesign specialty drug workflows.

For health systems now, the most important near-term step is preparation, not predicting what might happen. Organizations should evaluate their exposure while recognizing that the final rule may modify the proposed methodology.

Where Pressure May Emerge First

Initial reviews are likely to focus on high-cost, separately payable Part B drugs administered in hospital outpatient departments and provider-based clinics.

For example, oncology infusion may receive early attention because of drug cost, Medicare utilization, recurring administration, and the importance of outpatient drug margin to cancer care programs.

The issue, however, extends beyond oncology. Gastroenterology, rheumatology, immunology, ophthalmology, neurology, rare disease, and other advanced specialty areas may also require review when therapy costs, Medicare utilization, recurring administration, and site-of-care flexibility intersect.

Shifting Perspectives: From 340B Eligibility to Organizational Sustainability

For years, many health systems have managed outpatient drug economics through the lens of 340B eligibility. The proposed policy would not eliminate that question, but it would make eligibility alone insufficient.

A more durable strategy will require drug-level visibility into Medicare exposure, acquisition cost, reimbursement, billing logic, and site-specific operating cost.

That shift has practical implications. Pharmacy, finance, revenue cycle, compliance, and service-line leaders will need a shared view of which drugs are most exposed, which settings are most vulnerable, and which operational changes are feasible without increasing compliance, inventory, billing, or patient access risk.

What Health Systems Should Do Now to Prepare and Achieve More for Patient Health

1. Monitor the rulemaking process. Track the final CY 2027 OPPS rule, implementation timing, billing instructions, and any related litigation or agency

2. Build a drug-level exposure view. Rank separately payable Part B drugs by Medicare utilization, acquisition cost, reimbursement sensitivity, and service-line

3. Stress-test site-of-care economics. Review hospital outpatient departments, provider-based clinics, infusion centers, and specialty practices where payment changes could alter margin or access.

4. Confirm operational Assess whether pharmacy, revenue cycle, split-billing, chargemaster, inventory, and compliance processes can support any required changes.

5. Use scenario planning. Model potential outcomes under the proposed rule, a moderated final rule, phased implementation, exemptions, and service-line-specific

6. Engage cross-functional leadership Involve pharmacy, finance, revenue cycle, compliance, legal, clinical, and executive stakeholders before making purchasing or site-of-care decisions.

The proposal may change before it is finalized, but the direction is clear enough for health systems to begin preparing. Organizations that understand exposure at the drug, payer, and site-of-care level will be better positioned to protect access, maintain compliance, and set forth thoughtful decisions as the Medicare outpatient drug policy evolves.

This article is intended for informational purposes only and does not constitute legal, reimbursement, regulatory, clinical, or financial advice. Health systems should evaluate the proposed policy in consultation with their own legal, compliance, reimbursement, finance, and clinical leadership teams.

Sources:

1. https://www.cms.gov/newsroom/fact-sheets/calendar-year-2027-hospital-outpatient-prospective-payment-system-opps-ambulatory-surgical-center